To the Editor:

We read carefully the case report by Borges et al. and disagree that the case presented by them has frontotemporal dementia as the main diagnosis for the following reasons:

1) Demographically, the patient is in an advanced age group which speaks against FTD, classically a form of presenile dementia, further suggesting the most common dementia at senile age, namely AD;

2) The symptoms presented are much more characteristic of AD than FTD, especially psychosis (persecutory delusions) and topographic disorientation, both of which are very rare in FTD yet very common in AD.

3) The patient’s neuropsychological profile is much more consistent with AD because of the severe episodic memory and recognition deficits, cognitive functions usually preserved in FTD.

4) In terms of structural neuroimaging, her MRI is more characteristic of AD than FTD, since it discloses significant hippocampal atrophy (MTA=3), more markedly than frontal atrophy;

5) In terms of functional neuroimaging, similarly, her SPECT is more characteristic of AD than FTD, with intense temporal and hippocampal hypoperfusion, especially in the left side.

6) The patient had no cholinergic side effects with galantamine, which is compatible with AD and incompatible with FTD (FTD patients have many severe gastrointestinal effects when exposed to anticholinesterasic).

In addition to the above, it should be mentioned that the patient may not have responded to galantamine because the full therapeutic dose of the medication (24 mg/day) was not reached.

We suggest the most probable diagnosis in this case is the frontal variant of AD, or even the logopenic subtype of AD. Biomarkers would be useful to confirm this hypothesis, such as a CSF tau protein study.

Leonardo Ferreira Caixeta, MD, PhD
Federal University of Goiás, Goiânia GO, Brazil

REFERENCES
Episodic memory and recognition are functions that are generally preserved in the early stages of FTD. However, at the time of her first evaluation, our patient already presented with significant impairment in different functional domains, thereby characterizing a moderate to advanced phase of a dementia syndrome (CDR 2), with the possibility of progression to other impairments besides executive dysfunction, classically affected in patients with FTD. It is worth mentioning that the patient described also had psychiatric comorbidity (bipolar disorder), which has the potential to lead to impairments in memory and verbal recognition, including to an euthymic state.

Considering that the digitalized clipping of our patient’s neuroimaging data may not reveal all elements needed for a more accurate diagnosis, it is worth clarifying that all images were reviewed by two neuroradiologists from the university service, who identified global cerebral atrophy with frontal predominance. Furthermore, the presence of associated hippocampal atrophy is not a specific feature of Alzheimer’s disease, but rather supportive for its diagnosis, and which may be present in advanced stages of most cases of dementia syndromes.

Our patient presented with moderate to severe hypometabolism/hypoperfusion in the frontal and temporal regions, which is one of the criteria for the diagnosis of probable FTD.

After our patient started to take galantamine (8 mg with progression to 16 mg), she developed hyporexia and worse psychomotor agitation, a clinical picture described as possible side effects of anticholinesterases. There is even a concern with the use of acetylcholinesterase inhibitors in patients with bipolar 1 disorder, with some cases of manic shift described. Thus, due to the risk of malnutrition worsening and uncontrolled bipolar disorder, we opted to suspend galantamine and adjust antipsychotics.

In the present case, unfortunately, CSF biomarker examination, which could have been used as an aid in the differential diagnosis, was not performed. However, the identification of a profile compatible with dementia in Alzheimer’s disease (low amyloid β1-42 protein, and high TAU and p-TAU proteins) would not exclude the possibility (not ruled out) of neuroprogression in bipolar disorder.
Letters to the Editor

Saulo Queiroz Borges¹, Thiago Xavier Corrêa¹, Isabel Oliveira Azevedo Trindade², Rivadávio Fernandes Batista Amorim³, Maria Alice de Vilhena Toledo⁴.
¹MD, Universidade de Brasília (UnB), Hospital Universitário de Brasília (HUB), Brasilia, DF, Brazil. ²Ft, MSc, Universidade de Brasilia (UnB), Hospital Universitário de Brasília (HUB). ³MSc, PhD, Universidade de Brasília (UnB), Hospital Universitário de Brasília (HUB). ⁴MD, MSc, PhD, Universidade de Brasília (UnB), Hospital Universitário de Brasília (HUB), Brasilia, DF, Brazil.

REFERENCES